|
KMID : 1104820150030010011
|
|
Journal of Digestive Cancer Research
2015 Volume.3 No. 1 p.11 ~ p.16
|
|
|
Current and New Molecularly Targeted Agents for Metastatic Gastric Cancer
|
|
Park Sung-Chul
|
|
|
Abstract
|
|
|
|
The discovery of HER2, a biomarker in advanced gastric cancer, and successful clinical trial using trastuzumab that targets this biomarker signaled a revolutionary turning point in treatment of metastatic gastric cancer. Many studies about targeted agents for gastric cancer have been attempted. Among them, ramicirumab, a monoclonal antibody that targets vascular endothelial growth factor receptor-2 (VEGFR-2), and apatinib, a tyrosine kinase inhibitor (TKI) that targets VEGFR2, have shown to improve the survival rates in advanced gastric cancer patients, for whom previous therapies had failed; hence, they are expected to be accepted as one of the standard therapies for advanced gastric cancer.
|
|
|
KEYWORD
|
|
|
Stomach neoplasms, Trastuzumab, Ramucirumab, Apatinib
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|